# RxPONDER (NCT01272037)

> Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01272037
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma; Multicentric Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma
- Interventions: Anastrozole; Exemestane; Laboratory Biomarker Analysis; Letrozole; Quality-of-Life Assessment; Systemic Chemotherapy; Tamoxifen Citrate
- Enrollment: 5018
- Primary outcome: Invasive Disease-Free Survival (IDFS)

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses AMH and ovarian reserve as potential markers for guiding chemotherapy decisions in premenopausal patients, including whether some might avoid chemotherapy. It raises debate over whether chemotherapy’s contribution reflects ovarian suppression or direct cytotoxicity, and whether optimized ovarian function suppression plus endocrine therapy should be compared directly with chemotherapy. Discussion also covers cognitive effects, changing chemotherapy use and treatment uncertainty, as well as how RxPONDER defined menopausal status.

## Indexed commentary on RxPONDER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 83
- YouTube: 81
- Podcasts: 54

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rxponder-nct01272037

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01272037", "email": "<work email>"}; the inbox owner confirms by the emailed link.